CRLX101 (formerly IT-101)-A Novel Nanopharmaceutical of Camptothecin in Clinical Development.

Curr Bioact Compd

Cerulean Pharma Inc., 840 Memorial Drive, Cambridge MA 02139, USA.

Published: March 2011

CRLX101 (formerly IT-101) is a first-in-class nanopharmaceutical, currently in Phase 2a development, which has been developed by covalently conjugating camptothecin (CPT) to a linear, cyclodextrin-polyethylene glycol (CD-PEG) co-polymer that self-assembles into nanoparticles. As a nanometer-scale drug carrier system, the cyclodextrin polymeric nanoparticle technology, referred to as "CDP", has unique design features and capabilities. Specifically, CRLX101 preclinical and clinical data confirm that CDP can address not only solubility, formulation, toxicity, and pharmacokinetic challenges associated with administration of CPT, but more importantly, can impart unique biological properties that enhance CPT pharmacodynamics and efficacy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3182091PMC
http://dx.doi.org/10.2174/157340711795163866DOI Listing

Publication Analysis

Top Keywords

crlx101 it-101-a
4
it-101-a novel
4
novel nanopharmaceutical
4
nanopharmaceutical camptothecin
4
camptothecin clinical
4
clinical development
4
development crlx101
4
crlx101 it-101
4
it-101 first-in-class
4
first-in-class nanopharmaceutical
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!